Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Initial focus of partnership will aim to develop cancer therapeutics PLYMOUTH, Mich. and BOSTON , Jan. 5, 2023 /PRNewswire/ -- Esperovax, an innovative developer of oral mRNA biologics, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications.

Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

BOSTON , Jan. 4, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 11:15 a.m.

Ginkgo Bioworks Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference

Dermata Therapeutics

BitNile Holdings

Palisade Bio

Use these tips to make money with penny stocks The post How to Increase Your Chances of Consistent Penny Stocks Profits  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Increase Your Chances of Consistent Penny Stocks Profits

Guardant Health Inc

Novavax

As we head into New Year 2023, we wanted to take a look at some of the top biotech blunders of the last several months. While many biotech stocks can hold immense profit potential, others can wipe out your accounts in the blink of an eye.

Three Pharma Stocks to Sell Before They Die

Collaboration aims to leverage innovative biosecurity capabilities to promote public health, global health security, and the development of the bioeconomy BOSTON and GABORONE, Botswana , Dec. 20, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health ("MoH"), representing the Government of the Republic of Botswana, today announced that they have entered into a Memorandum of Understanding ("MoU") with the intent of developing and implementing new biosecurity capabilities in Botswana. The planned partnership will support capacity-building and biosecurity throughout Botswana's public health sector.

Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Plans to Develop and Implement New Biosecurity Capabilities in Botswana

Carnival

Coinbase

Macy's

Redfin

Vroom

The worst stocks to buy in a bear market are those whose financials can't withstand long periods of uncertainty. As we look ahead to 2023, equity investors hoping for better returns may be in for a tough year.

The 7 Worst Stocks to Buy in a Bear Market

Arlo Technologies Inc

Holley

LianBio

Viking Therapeutics

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Top Wall Street Firm Has 5 Stocks Under $10 With 160% to 970% Upside Potential

Enzyme Intelligence Virtual Event on December 15, 2022 gives overview of Ginkgo's approach to machine learning-guided enzyme engineering BOSTON , Dec. 8, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the launch of Ginkgo Enzyme Services . Ginkgo Enzyme Services is powered by ultra high throughput screening and machine learning-guided protein design, as well as optimized proprietary bacterial and fungal host strains.

Ginkgo Bioworks Launches Ginkgo Enzyme Services, Enabling Applications across Pharmaceuticals and Diagnostics, Food and Agriculture, and Beyond

Kinross Gold

Summit Therapeutics

Use these tips for buying penny stocks next year The post Thinking of Buying Penny Stocks in 2023? 4 Things to Know  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Thinking of Buying Penny Stocks in 2023? 4 Things to Know

The company's strategy will take time to implement, but it'll make investors a lot richer if it works.

Down 76% This Year, Is This Growth Stock Now a Screaming Buy?

Nokia

VEON

Use these trading strategies for buying penny stocks in 2022 The post Different Penny Stocks Trading Strategies in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Different Penny Stocks Trading Strategies in 2022

Agenus

Amyris

Canopy Growth

Globalstar

Nordic American Tankers

Qurate Retail Inc

Transocean

SoFi Technologies

Penny stocks to watch with unusual options activity this week. The post 10 Top Penny Stocks With Unusual Options Activity, Time To Buy?

10 Top Penny Stocks With Unusual Options Activity, Time To Buy?

PaxMedica Inc

Check out these reasons to buy penny stocks in 2022 The post Are Penny Stocks too Risky to Invest In? 3 Reasons to Consider  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are Penny Stocks too Risky to Invest In? 3 Reasons to Consider

Penny stocks to watch with unusual options activity this week. The post 7 Top Penny Stocks With Unusual Options Activity, Time To Buy?

7 Top Penny Stocks With Unusual Options Activity, Time To Buy?

This week has proven to be a rough one for investors in Ginkgo Bioworks (NYSE: DNA ) stock. After announcing a $100 million public offering, DNA stock has lost more than 20% of its value in the past five days alone.

Cathie Wood Keeps Buying Ginkgo Bioworks (DNA) Stock

BOSTON , Nov. 16, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading platform for cell programing and biosecurity, today announced the sale of shares of  its Class A common stock for gross proceeds of approximately $100 million to BTIG, LLC, as the underwriter in the registered public offering of those shares. In connection with this offering, Ginkgo has granted the underwriter a 30-day option to purchase up to an additional $15 million of  shares of Class A common stock.

Ginkgo Announces Public Offering of Class A Common Stock

Company announces $100 million equity offering. Q3 revenues beat and yearly forecast raised.

Ginkgo Bioworks: Strange Equity Offering

BOSTON , Nov. 15, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"),which is building the leading platform for cell programing and biosecurity, today announced that it intends to offer and sell $100 million of its Class A common stock in an underwritten public offering. As part of this offering, Ginkgo intends to grant the underwriter a 30-day option to purchase up to an additional $15 million of the shares of Class A common stock.

Ginkgo Bioworks Announces Proposed Public Offering of Class A Common Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Anna Marie Wagner - Senior Vice President-Corporate Development Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Steve Mah - Cowen Mark Massaro - BTIG Anna Marie Wagner Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.

Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2022 Earnings Call Transcript

15 new Cell Programs added and $66 million of Total revenue in Q3 2022 Closed four acquisitions in October, including Zymergen and Bayer's West Sacramento agricultural biologicals capabilities, enabling commencement of integration and pursuit of new growth opportunities End of quarter cash balance of over $1.3 billion provides continued financial flexibility BOSTON , Nov. 14, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2022. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Third Quarter 2022 Financial Results

Strain development program aims to accelerate efforts to create sustainable chemicals BERKELEY, Calif. and BOSTON , Nov. 11, 2022 /PRNewswire/ -- Lygos, Inc., a vertically integrated provider of sustainable specialty ingredients, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a multi-product research and development collaboration designed to optimize and scale production of sustainable specialty ingredients that can replace toxic petrochemistry, reclaim local manufacturing, and advance industrial bio-innovation.

Lygos and Ginkgo Bioworks Announce Partnership to Optimize Production of Biobased Specialty Chemicals

Poster presentation at SITC 2022 highlights high throughput methods for discovery of novel CAR designs with improved persistence BOSTON , Nov. 9, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it will be presenting a poster on November 11 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The poster highlights Foundry-enabled methods for large-scale, combinatorial library design and screening of Chimeric Antigen Receptor (CAR) domains for improved persistence.

Ginkgo Bioworks To Present New Data on High Throughput Pooled Screening Method to Discover Novel CAR-T Designs for Solid Tumors

NEW YORK , Nov. 7, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA). If you are a shareholder of Ginkgo Bioworks Holdings, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/ginkgo-bioworks-holdings-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Ginkgo Bioworks Holdings, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Presentation and Q&A session scheduled for post-market on Monday, November 14, 2022 BOSTON , Nov. 7, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2022, on Monday, November 14, 2022, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Announces Date of Third Quarter 2022 Results Presentation

Ambev

ESSA Pharma

Check these strategies out for buying penny stocks right no The post 3 Beginner Penny Stocks Trading Mistakes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Ginkgo Bioworks Holdings Stock (DNA)